ALKS$45.691.78%0.80
After Hours: 45.690.00 0.00%
Alkermes Plc (ALKS)
Date: 2026-11-03 16:00O: 46.17H: 47.43L: 45.22C: 45.69Vol: 2.330M
Alkermes Plc stock is traded at $45.69, with a volume of 2,330,056. It is up +1.78% in the last 24 hours and up +9.44% over the past month. Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Previous Close:
$44.89
Open:
$46.17
24h Volume:
2,330,056
Relative Volume:
1.50
Market Cap:
$7.67B
Revenue:
$1.56B
Net Income/Loss:
$152.72M
P/E Ratio:
50.80
EPS:
$0.8994
Net Cash Flow:
$221.80M
1W Performance:
+3.09%
1M Performance:
+9.44%
6M Performance:
+36.88%
1Y Performance:
+51.44%
1-Day Range:
$45.22$47.43
1-Week Range:
$44.49$47.43
52-Week Range:
$27.00$55.67
Alkermes Plc Stock (ALKS) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
Alkermes Plc Stock (ALKS) Financials Data
Alkermes Plc Stock (ALKS) Insider Trading
- Gaffin David JosephNov 03 '26Officer
- Transaction
- Proposed Sale
- Cost
- $46.17
- #Shares
- 2,035
- Value ($)
- 93,956
- #Shares Total
- 0
- Gaffin David JosephOct 02 '26EVP, CLO, Alkermes, Inc.
- Transaction
- Sale
- Cost
- $41.03
- #Shares
- 2,034
- Value ($)
- 83,455
- #Shares Total
- 221,388
- Gaffin David JosephOct 02 '26Officer
- Transaction
- Proposed Sale
- Cost
- $41.03
- #Shares
- 2,034
- Value ($)
- 83,455
- #Shares Total
- 0
- Gaffin David JosephSep 03 '26EVP, CLO, Alkermes, Inc.
- Transaction
- Sale
- Cost
- $48.01
- #Shares
- 2,034
- Value ($)
- 97,652
- #Shares Total
- 223,422
- Gaffin David JosephSep 03 '26Officer
- Transaction
- Proposed Sale
- Cost
- $48.01
- #Shares
- 2,034
- Value ($)
- 97,652
- #Shares Total
- 0
- Hopkinson Craig C.Sep 01 '26EVP R&D, Chief Medical Officer
- Transaction
- Option Exercise
- Cost
- $24.59
- #Shares
- 5,000
- Value ($)
- 122,950
- #Shares Total
- 74,389
- Hopkinson Craig C.Sep 01 '26EVP R&D, Chief Medical Officer
- Transaction
- Sale
- Cost
- $46.99
- #Shares
- 9,000
- Value ($)
- 422,874
- #Shares Total
- 65,389
- Hopkinson Craig C.Sep 01 '26Officer
- Transaction
- Proposed Sale
- Cost
- $46.99
- #Shares
- 9,000
- Value ($)
- 422,874
- #Shares Total
- 0
- Nichols Christian ToddAug 17 '26Officer
- Transaction
- Proposed Sale
- Cost
- $49.23
- #Shares
- 7,576
- Value ($)
- 372,937
- #Shares Total
- 0
- Nichols Christian ToddAug 17 '26SVP, Chief Commercial Officer
- Transaction
- Sale
- Cost
- $49.23
- #Shares
- 7,576
- Value ($)
- 372,937
- #Shares Total
- 102,193
